RBC Capital Maintains Outperform on Ardent Health, Raises Price Target to $18
Benzinga Newsdesk 1 day ago
Analyst RatingsNewsPrice Target
RBC Capital analyst Ben Hendrix maintains Ardent Health (NYSE:ARDT) with a Outperform and raises the price target from $13 to $18.
RBC Capital analyst Ben Hendrix maintains Ardent Health (NYSE:ARDT) with a Outperform and raises the price target from $13 to $18.